However, the experimental setting is completely different: in myeloid cells, the cross-linking of LAIR1 is triggered by a second reagent recognizing an anti-LAIR1-specific monoclonal antibody, while for RCC this setting has not been assessed. The gene discussed is LAIR1; the disease is renal cell carcinoma.